Pfizer (PFE) Earnings: Results, Guidance and Stock Reaction
Pfizer's latest report was Q3 2026 on November 3, 2026 (before the open): Beat and raise, and the stock moved -2.0% on it. Below: the numbers vs Wall Street, then every quarter we've explained in plain English.
Latest: Q3 2026 vs consensus
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $0.87 | $0.73 (LSEG) | Beat |
| Revenue | $16.58B (flat y/y) | $15.87B (LSEG) | Beat |
| FY2026 revenue guidance | $62.0-$64.0B (was $60.5-$62.5B) | $62.2B (Investing.com) | Raised, in line |
| FY2026 adj. EPS guidance | $2.95-$3.05 (was $2.80-$3.00) | $2.96 (Reuters) | Raised, in line |
Full PFE Q3 2026 explainer: what mattered, the reaction and Max's verdict →
Every Pfizer report we've explained
- Q3 2026 (November 3, 2026, before the open): Beat and raise · stock -2.0% after
Get the next PFE report explained in your inbox.
Every big earnings report in plain English: beat or miss, guidance, and how the stock took it. No spam, unsubscribe anytime.
FAQ
Did Pfizer (PFE) beat earnings last quarter?
In Q3 2026, reported November 3, 2026, Pfizer came in Beat and raise. Adjusted EPS: $0.87 vs $0.73 (LSEG); Revenue: $16.58B (flat y/y) vs $15.87B (LSEG); FY2026 revenue guidance: $62.0-$64.0B (was $60.5-$62.5B) vs $62.2B (Investing.com).
When did Pfizer last report earnings?
Pfizer reported Q3 2026 results on November 3, 2026, before the open.
Get tomorrow's five at 7 AM, free.
Max Edge's Bold Bet of the Day plus every pick graded in public, before the opening bell.